A Multicenter, Open Phase I Clinical Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-1826 for Injection in Patients With Advanced Solid Tumors
Latest Information Update: 11 Aug 2025
At a glance
- Drugs SHR 1826 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 18 Feb 2024 Status changed from not yet recruiting to recruiting.
- 30 Oct 2023 New trial record